TY - JOUR
T1 - Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals
AU - van der Lugt, Jasper
AU - Gorowara, Meena
AU - Avihingsanon, Anchalee
AU - Burger, David
AU - Sringam, Kancharat
AU - Kerr, Stephen
AU - Wit, Ferdinand
AU - Lange, Joep
AU - Ruxrungtham, Kiat
PY - 2009
Y1 - 2009
N2 - Currently, the optimal boosting dose for saquinavir is unknown. Therefore, we evaluated the pharmacokinetics profiles in a cross over setting comparing saquinavir/ritonavir 1500/50 mg (plus NRTI backbone) to saquinavir/ritonavir 1500/100 mg in the same HIV-infected, Thai individuals. The 50% reduction of ritonavir boosting did not result in a change in the pharmacokinetics of saquinavir, whereas the ritonavir exposure was significantly lower when a dose of 50 mg was administered
AB - Currently, the optimal boosting dose for saquinavir is unknown. Therefore, we evaluated the pharmacokinetics profiles in a cross over setting comparing saquinavir/ritonavir 1500/50 mg (plus NRTI backbone) to saquinavir/ritonavir 1500/100 mg in the same HIV-infected, Thai individuals. The 50% reduction of ritonavir boosting did not result in a change in the pharmacokinetics of saquinavir, whereas the ritonavir exposure was significantly lower when a dose of 50 mg was administered
U2 - https://doi.org/10.1097/QAD.0b013e32832b4461
DO - https://doi.org/10.1097/QAD.0b013e32832b4461
M3 - Article
C2 - 19451794
SN - 0269-9370
VL - 23
SP - 1176
EP - 1179
JO - AIDS (London, England)
JF - AIDS (London, England)
IS - 9
ER -